These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 25365636)

  • 1. Contrast-enhanced ultrasound evaluation of the renal microcirculation response to terlipressin in hepato-renal syndrome: a preliminary report.
    Schneider AG; Schelleman A; Goodwin MD; Bailey M; Eastwood GM; Bellomo R
    Ren Fail; 2015 Feb; 37(1):175-9. PubMed ID: 25365636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contrast-enhanced ultrasonography to evaluate changes in renal cortical microcirculation induced by noradrenaline: a pilot study.
    Schneider AG; Goodwin MD; Schelleman A; Bailey M; Johnson L; Bellomo R
    Crit Care; 2014 Dec; 18(6):653. PubMed ID: 25439317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study.
    Ortega R; Ginès P; Uriz J; Cárdenas A; Calahorra B; De Las Heras D; Guevara M; Bataller R; Jiménez W; Arroyo V; Rodés J
    Hepatology; 2002 Oct; 36(4 Pt 1):941-8. PubMed ID: 12297842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study.
    Moreau R; Durand F; Poynard T; Duhamel C; Cervoni JP; Ichaï P; Abergel A; Halimi C; Pauwels M; Bronowicki JP; Giostra E; Fleurot C; Gurnot D; Nouel O; Renard P; Rivoal M; Blanc P; Coumaros D; Ducloux S; Levy S; Pariente A; Perarnau JM; Roche J; Scribe-Outtas M; Valla D; Bernard B; Samuel D; Butel J; Hadengue A; Platek A; Lebrec D; Cadranel JF
    Gastroenterology; 2002 Apr; 122(4):923-30. PubMed ID: 11910344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response.
    Sharma P; Kumar A; Shrama BC; Sarin SK
    Am J Gastroenterol; 2008 Jul; 103(7):1689-97. PubMed ID: 18557715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Response to Terlipressin and albumin is associated with improved outcome in patients with cirrhosis and hepatorenal syndrome].
    Nguyen-Tat M; Götz E; Scholz-Kreisel P; Ahrens J; Sivanathan V; Schattenberg J; Rey JW; Wörns MA; Galle PR; Marquardt JU
    Dtsch Med Wochenschr; 2015 Jan; 140(2):e21-6. PubMed ID: 25612289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study.
    Ghosh S; Choudhary NS; Sharma AK; Singh B; Kumar P; Agarwal R; Sharma N; Bhalla A; Chawla YK; Singh V
    Liver Int; 2013 Sep; 33(8):1187-93. PubMed ID: 23601499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of terlipressin and albumin in patients with type 1 hepatorenal syndrome: a multicenter, open-label, explorative study.
    Narahara Y; Kanazawa H; Sakamoto C; Maruyama H; Yokosuka O; Mochida S; Uemura M; Fukui H; Sumino Y; Matsuzaki Y; Masaki N; Kokubu S; Okita K
    J Gastroenterol; 2012 Mar; 47(3):313-20. PubMed ID: 22038555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contrast-enhanced ultrasound to evaluate changes in renal cortical perfusion around cardiac surgery: a pilot study.
    Schneider AG; Goodwin MD; Schelleman A; Bailey M; Johnson L; Bellomo R
    Crit Care; 2013 Jul; 17(4):R138. PubMed ID: 23849270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcome of patients treated with terlipressin for types 1 and 2 hepatorenal syndrome.
    Testro AG; Wongseelashote S; Angus PW; Gow PJ
    J Gastroenterol Hepatol; 2008 Oct; 23(10):1535-40. PubMed ID: 17784863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.
    Martín-Llahí M; Pépin MN; Guevara M; Díaz F; Torre A; Monescillo A; Soriano G; Terra C; Fábrega E; Arroyo V; Rodés J; Ginès P;
    Gastroenterology; 2008 May; 134(5):1352-9. PubMed ID: 18471512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Terlipressin Improves Renal Function and Reverses Hepatorenal Syndrome in Patients With Systemic Inflammatory Response Syndrome.
    Wong F; Pappas SC; Boyer TD; Sanyal AJ; Bajaj JS; Escalante S; Jamil K;
    Clin Gastroenterol Hepatol; 2017 Feb; 15(2):266-272.e1. PubMed ID: 27464593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study.
    Mulkay JP; Louis H; Donckier V; Bourgeois N; Adler M; Deviere J; Le Moine O
    Acta Gastroenterol Belg; 2001; 64(1):15-9. PubMed ID: 11322061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Treatment of Hepatorenal Syndrome.
    Cavallin M; Fasolato S; Marenco S; Piano S; Tonon M; Angeli P
    Dig Dis; 2015; 33(4):548-54. PubMed ID: 26159272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.
    Cavallin M; Kamath PS; Merli M; Fasolato S; Toniutto P; Salerno F; Bernardi M; Romanelli RG; Colletta C; Salinas F; Di Giacomo A; Ridola L; Fornasiere E; Caraceni P; Morando F; Piano S; Gatta A; Angeli P;
    Hepatology; 2015 Aug; 62(2):567-74. PubMed ID: 25644760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis.
    Rodríguez E; Elia C; Solà E; Barreto R; Graupera I; Andrealli A; Pereira G; Poca M; Sánchez J; Guevara M; Soriano G; Alessandria C; Fernández J; Arroyo V; Ginès P
    J Hepatol; 2014 May; 60(5):955-61. PubMed ID: 24447876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Terlipressin therapy for renal failure in cirrhosis.
    Triantos CK; Samonakis D; Thalheimer U; Cholongitas E; Senzolo M; Marelli L; Leandro G; Patch D; Burroughs AK
    Eur J Gastroenterol Hepatol; 2010 Apr; 22(4):481-6. PubMed ID: 19952764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Terlipressin in 30 patients with hepatorenal syndrome: results of a retrospective study.
    von Kalckreuth V; Glowa F; Geibler M; Lohse AW; Denzer UW
    Z Gastroenterol; 2009 Jan; 47(1):21-6. PubMed ID: 19156588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Terlipressin and gelafundin: safe therapy of hepatorenal syndrome.
    Saner F; Kavuk I; Lang H; Biglarnia R; Frühauf NR; Schäfers RF; Malagó M; Broelsch CE
    Eur J Med Res; 2004 Feb; 9(2):78-82. PubMed ID: 15090293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics.
    Boyer TD; Sanyal AJ; Garcia-Tsao G; Blei A; Carl D; Bexon AS; Teuber P;
    J Hepatol; 2011 Aug; 55(2):315-21. PubMed ID: 21167235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.